Short Interest in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Decreases By 15.1%

Barinthus Biotherapeutics plc (NASDAQ:BRNS) saw a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 10,100 shares, a decrease of 15.1% from the March 15th total of 11,900 shares. Based on an average daily trading volume, of 21,400 shares, the short-interest ratio is currently 0.5 days. Approximately 0.0% of the shares of the stock are short sold.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. HC Wainwright dropped their price target on Barinthus Biotherapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, March 21st. William Blair reaffirmed an “outperform” rating on shares of Barinthus Biotherapeutics in a research note on Monday, January 8th.

Barinthus Biotherapeutics Stock Performance

Shares of NASDAQ:BRNS traded down $0.11 during trading on Tuesday, hitting $2.53. The company had a trading volume of 18,051 shares, compared to its average volume of 20,297. The company has a market cap of $98.47 million, a PE ratio of -1.38 and a beta of -0.52. Barinthus Biotherapeutics has a one year low of $1.64 and a one year high of $5.10. The stock has a fifty day moving average price of $2.69.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its quarterly earnings results on Wednesday, March 20th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.10. As a group, research analysts anticipate that Barinthus Biotherapeutics will post -2.6 EPS for the current year.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.